Bizarre Patents
A sealed crustless sandwich for providing a convenient sandwich without an outer crust which can be stored for long periods of time without a central filling from leaking outwardly.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7524816 | Peptides and supported peptides for treating skin diseases The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some part... | 04/28/2009 |
| 7524817 | Therapies for chronic renal failure The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certa... | 04/28/2009 |
| 7521422 | Use of aspartic proteases in cosmetics and therapeutics The invention provides a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one purified natural or synthetic polypeptide wherein the peptide sequence is represented wholly or partly by at least one sequence selected ... | 04/21/2009 |
| 7521423 | Exendin pharmaceutical compositions Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevat... | 04/21/2009 |
| 7521424 | Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic ac... | 04/21/2009 |
| 7517855 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compos... | 04/14/2009 |
| 7517856 | Bioconjugates comprising sulfated polysaccharides and their uses The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can... | 04/14/2009 |
| 7514405 | Methods for treating transplant rejection Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an... | 04/07/2009 |
| 7514406 | Methods for inhibiting deacetylase activity A method for identifying a compound that inhibits the NAD+-dependent deacetylase activity of a SIR2 protein is disclosed. These compounds are useful for the treatment of cancers and other diseases, through the activation of silenced genes, through the pro... | 04/07/2009 |
| 7511016 | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof The present invention provides methods and compositions for the treatment, diagnosis, and prevention of diseases, such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods include th... | 03/31/2009 |
| 7511015 | Modified defensins and their use This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also pr... | 03/31/2009 |
| 7511017 | Methods of treatment with TNFR5 The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor n... | 03/31/2009 |
| 7511018 | Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresp... | 03/31/2009 |
| 7511019 | Method of treating coronary artery disease by administering FGF-4 The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present ... | 03/31/2009 |
| 7507715 | Methods useful in the treatment of bone resorption diseases The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after... | 03/24/2009 |
| 7507716 | Method for treating pain with prolactin antagonists The embodiments disclosed herein provide methods for inhibiting, reducing and/or treating pain in a subject by administering to a subject in need thereof a pharmaceutical formulation that includes a pharmacologically active compound that is adapted to disrupt PRL si... | 03/24/2009 |
| 7507713 | Motoneuronotrophic factor The present invention is directed to a novel purified polypeptide consisting of an amino acid sequence as set forth in SEQ ID NO: 4, one of the member of the Motoneuronotrophic Factor family which has shown to have diagnostic and therapeutic applications in mammals.... | 03/24/2009 |
| 7507712 | NOV protein: an anti-angiogenic agent and its use, in particular for the treatment of cancer The present invention relates to the use of a protein characterized in that it comprises or is constituted by the NOV protein, represented by the sequence SEQ ID NO: 2, or a fragment of this protein, providing that this fragment exhibits an angiogenesis-inhibiting a... | 03/24/2009 |
| 7507714 | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. ... | 03/24/2009 |
| 7507711 | Peptide inhibitors of protein kinase C PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations... | 03/24/2009 |
| 7504379 | Protection of cardiac myocardium The invention provides compositions and methods for protecting vascular tissues from injury that occurs, for example, during occlusion of one or more arteries. In some embodiments, the injury is myocardial infarction. The compositions of the invention include combin... | 03/17/2009 |
| 7501396 | Methods for treating joint pain using poly-gamma-glutamic acid Methods for treating joint pain such as temporomandibular joint disorders, osteoarthritis of the knee, hip and other types of inflammatory joint diseases. The methods involve the use of poly-gamma-glutamic acid. ... | 03/10/2009 |
| 7501394 | Compounds for targeting hepatocytes We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro. ... | 03/10/2009 |
| 7501395 | Method of screening for antianxiety drugs An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of... | 03/10/2009 |
| 7498306 | Peptides binding to the phosphatase 2A protein The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or ... | 03/03/2009 |
| 7498307 | Combinations of DnaK inhibitors with known antibacterial agents Compositions, methods and kits are provided comprising (a) a therapeutically effective amount of a DnaK inhibitor; and (b) a therapeutically effective amount of a known antibacterial agent. Such compositions, methods and kits are useful in the treatment of various b... | 03/03/2009 |
| 7498308 | Method of treating a subject suffering stroke comprising administering Glucagon-like peptide-1 analogs Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 com... | 03/03/2009 |
| 7498305 | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two ex... | 03/03/2009 |
| 7498303 | GNRH analogues for treatment of urinary incontinence The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovarectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and sk... | 03/03/2009 |
| 7498304 | Angiogenesis-modulating compositions and uses Hedgehog agonists and antagonists can be used to regulate angiogenesis, and to prevent angiogenesis driven pathologies. Furthermore, hedgehog agonists and antagonists have utility in modulating tissue repair and in the treatment of many forms of cancer. ... | 03/03/2009 |
| 7494977 | Polypeptides homologous to VEGF and BMP1 The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF inclu... | 02/24/2009 |
| 7494978 | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders. ... | 02/24/2009 |
| 7494976 | Caveolin peptides and their use as therapeutics The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize pepti... | 02/24/2009 |
| 7491700 | Conversion of apoptotic proteins Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing ap... | 02/17/2009 |
| 7491696 | Proteolysis resistant active VEGF The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according ... | 02/17/2009 |
| 7491697 | Muteins of fibroblast growth factor 21 The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propa... | 02/17/2009 |
| 7491698 | Mixing and matching TC proteins for pest control The subject invention relates to the surprising discovery that toxin complex (TC) proteins, obtainable from Xenorhabdus, Photorhabdus, and Paenibacillus, can be used interchangeably with each other. In particularly preferred embodiments of the subject ... | 02/17/2009 |
| 7491699 | Peptide nanostructures and methods of generating and using the same A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid. ... | 02/17/2009 |
| 7488716 | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders. ... | 02/10/2009 |
| 7488713 | Cancer treatment using C-type natriuretic peptides The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only survivi... | 02/10/2009 |
